BioCentury
ARTICLE | Clinical News

Ceftobiprole meets Phase III cSSSI endpoint

March 3, 2006 2:52 AM UTC

Ceftobiprole ( BAL5788) from Basilea (SWX:BSLN) and Johnson & Johnson (JNJ) met the primary endpoint of non-inferiority to vancomycin in the Phase III STRAUSS trial to treat Gram-positive complicated skin and skin structure infections (cSSSIs). In the double-blind, international trial in 784 patients, about 93.3% of patients given ceftobriprole were clinically cured vs. 93.5% patients given vancomycin. ...